secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-210299
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Beam Therapeutics Reports Q1 2026 Results; BEAM-302 Pivotal Cohort and Risto-cel BLA on Track
--------------------------------------------------------------------------------

- BEAM-302 Phase 1/2 data showed single-dose safety and efficacy; 60 mg selected as optimal dose; global pivotal cohort to start H2 2026.
- Risto-cel (BEAM-101) Phase 1/2 data published in NEJM; BLA submission expected as early as year-end 2026 for sickle cell disease.
- Cash, cash equivalents and marketable securities were $1.2 billion as of March 31, 2026; cash runway into mid-2029.
- Net loss of $94.3 million ($0.91 per share) for Q1 2026, compared to net loss of $108.3 million ($1.23 per share) in Q1 2025.
- IND filing for BEAM-304 in PKU and initial data for BEAM-301 in GSDIa expected in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000119312526210299/0001193125-26-210299-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000119312526210299/beam-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-210299

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer